| Autor: |
Udawela M; Molecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia., Scarr E; Molecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.; Department of Psychiatry, University of Melbourne, Parkville, VIC Australia., Boer S; Molecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia., Um JY; Molecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.; Cardiovascular and Neurology Products Division, Drug Evaluation Department, National Institute of Food and Drug Safety Evaluation, Osong Health Technology Administration Complex, Chungcheongbuk-do, South Korea., Hannan AJ; Epigenetics and Neural Plasticity Laboratory, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia., McOmish C; Molecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia., Felder CC; Lilly Research Laboratories, Neuroscience Research Division, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN USA., Thomas EA; Department of Molecular and Cellular Neuroscience, The Scripps Research Institute, La Jolla, CA USA., Dean B; Molecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.; Cardiovascular and Neurology Products Division, Drug Evaluation Department, National Institute of Food and Drug Safety Evaluation, Osong Health Technology Administration Complex, Chungcheongbuk-do, South Korea. |
| Abstrakt: |
Our previous study demonstrated that phospholipase C beta 1 mRNA was down-regulated in Brodmann's area 46 from subjects with schizophrenia. However, phospholipase C beta 1 protein has also been shown to be lower in Brodmann's area 8 and 9 from teenage suicide subjects, creating a potential confound in interpreting the findings in schizophrenia due to the high suicide rate associated with this disorder. To begin to reconcile and consolidate these findings, in this study, we measured mRNA and protein levels of phospholipase C beta 1 variants a and b in Brodmann's area 46 and Brodmann's area 9 from subjects with schizophrenia, many of whom were suicide completers, and determined the diagnostic specificity of observed findings. Consistent with our previous study, levels of phospholipase C beta 1 a and b mRNA, but not protein, were lower in Brodmann's area 46 from subjects with schizophrenia. In Brodmann's area 9, phospholipase C beta 1a protein levels were lower in subjects with schizophrenia, while phospholipase C beta 1b mRNA was higher and protein was lower in those that had died of suicide. Altered protein levels in Brodmann's area 9 appeared to be diagnostically specific, as we did not detect these changes in subjects with bipolar disorder, major depressive disorder or suicide completers with no diagnosis of mental illness. We further assessed the relationship between phospholipase C beta 1 and levels of muscarinic receptors (CHRMs) that signal through this protein, in both human and Chrm knockout mouse central nervous system tissue, and found no strong relationship between the two. Understanding central nervous system differences in downstream effector pathways in schizophrenia may lead to improved treatment strategies and help to identify those at risk of suicide. |
Full text from SpringerLink